Generation and characterization of anti-AA amyloid-specific monoclonal antibodies.

Frontiers in Immunology
Jonathan S WallDale Schenk

Abstract

AA amyloidosis results from the pathologic deposition in the kidneys and other organs of fibrils composed of N-terminal fragments of serum amyloid A protein (SAA). Given that there are only limited means to visualize these deposits, we have developed a series of mAbs, 2A4, 7D8, and 8G9, that bind specifically with nanomolar affinity to a carboxy-terminal epitope generated following proteolysis of SAA that yields the predominant component of AA amyloid deposits. Notably, these antibodies do not recognize native SAA, they retain their immunoreactivity when radiolabeled with I-125 and, after injection into AA amyloidotic mice, localize, as evidenced by autoradiography and micro-single photon emission computed tomography imaging, to histologically confirmed areas of amyloid deposition; namely, spleen, liver, and pancreas. The results of our in vitro and in vivo studies demonstrate the AA fibril-selectivity of mAbs 2A4, 7D8, and 8G9 and warrant further investigation into their role as novel diagnostic agents for patients with AA amyloidosis.

Citations

Sep 23, 2018·Blood·Cindy VargaRaymond L Comenzo
Jul 18, 2019·JACC. Basic to Translational Science·Kathleen W ZhangDaniel J Lenihan
Jun 12, 2020·Acta Haematologica·Layla Van Doren, Suzanne Lentzsch

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
ELISA
size-exclusion liquid chromatography
X-ray
light microscopy

Software Mentioned

Image Pro Plus
SigmaPlot
SPSS
Excel
Amira
MediaCybernetics

Related Concepts

Related Feeds